, prescribers were required to select an indication as part of an antimicrobial (AM) order; "other" was an option. In 2011, Centers for Medicare and Medicaid Service (CMS) added "antibiotic orders include an indication for use" as part of its surveyor worksheet. We initiated a daily review of active AM orders with "other" as the indication in April 2012. The goal of this project is to describe our two year experience with this process.
Methods. Our hospital utilizes EPIC (Madison, WI) as our electronic health record (EHR). The on-call ID physician ran a daily report of active AM orders with indication other, reviewed the clinical record, and documented agreement or recommended interventions in the EHR. We performed a retrospective chart review to assess the acceptance of those recommendations.
Results. During the study period, there were 43,384 AM orders, 18% had "other" as the indication. We reviewed 3851 orders with "other" as the listed indication of which 196 (5%) required interventions. There was variability in the acceptance rate by type of intervention: Multiple interventions were suggested in 12% of reviews. The recommended intervention was accepted 74% of the time. The acceptance rate was similar in ICU and non-ICU patient care settings.
We noted differences in ordering patterns by AM class. Fluoroquinolones comprised 2% of all AM orders which represented 9% of all indication "other" orders. This class made up 9% of our interventions. Nebulized tobramycin was 0.6% of total AM orders but 2.5% of orders with an "other" indication.
Conclusion. 5% of all AM orders with indication "other" required an intervention, the majority of which were accepted. Some AM classes were overrepresented in the indication "other" orders but had a similar rate of intervention. This offers an opportunity to refine the approved indication list and provide additional prescriber education. In anticipation of a CMS requirement for AM indication, ASPs should carefully select preapproved indications for AMs.
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